1. Visual loss treated with osimertinib: A case report
- Author
-
Dimitrios Drekolias, Scott D. Walter, and Todd Alekshun
- Subjects
Non-small cell lung cancer ,Choroidal metastasis ,Osimertinib ,Tyrosine kinase inhibitor ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Visual loss secondary to choroidal metastases is a rare initial presentation of lung cancer. Osimertinib is a third generation TKI used in treating advanced EGFR-mutation positive lung cancer. We present, to the best of our knowledge, the second published case of an EGFR-mutation positive non-small cell lung cancer (NSCLC) presenting as a choroidal metastasis and treated with osimertinib as first-line therapy.
- Published
- 2022
- Full Text
- View/download PDF